Pharsight

Drug Patents owned by Bristol

1. List of Camzyos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9181200 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 28, 2029
New Chemical Entity Exclusivity (NCE) Apr 28, 2027

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: 2026-04-28

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

More Information on Dosage

CAMZYOS family patents

12

United States

4

Australia

3

Israel

3

Korea, Republic of

3

Japan

2

Singapore

2

China

EA

2

EA

2

European Union

1

South Africa

1

Denmark

1

Mexico

1

Hong Kong

1

Slovenia

1

Lithuania

1

Hungary

1

Morocco

1

Philippines

1

Costa Rica

1

Croatia

1

Brazil

1

Portugal

1

Guatemala

1

Malaysia

1

Spain

1

Dominican Republic

1

Peru

1

Poland

1

Chile

1

RS

1

Ukraine

1

Canada

1

Tunisia

1

New Zealand

2. List of Onureg drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571436 BRISTOL NA
May, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 1, 2023
Orphan Drug Exclusivity (ODE) Sep 1, 2027

Drugs and Companies using AZACITIDINE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ONUREG before it's patent expiration?
More Information on Dosage

3. List of Sotyktu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47929 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
Nov, 2033

(10 years from now)

US10000480 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021475 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 9, 2027

Drugs and Companies using DEUCRAVACITINIB ingredient

NCE-1 date: 2026-09-09

Market Authorisation Date: 09 September, 2022

Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are canididates for systemic therapy or phototherapy

Dosage: TABLET;ORAL

More Information on Dosage

SOTYKTU family patents

9

United States

4

Australia

3

Singapore

3

Japan

3

European Union

2

Denmark

2

Mexico

2

Slovenia

2

Lithuania

2

Hungary

2

Croatia

2

Portugal

2

Spain

2

Poland

2

RS

1

South Africa

1

Turkey

1

Hong Kong

1

Morocco

1

Philippines

1

Uruguay

1

Argentina

1

Brazil

1

Cyprus

1

Malaysia

1

Korea, Republic of

1

Peru

1

Chile

1

Taiwan, Province of China

1

China

EA

1

EA

1

Canada

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic